world copd day chronic obstructive pulmonary disease press conference kyoto, japan november 19, 2006
TRANSCRIPT
![Page 1: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/1.jpg)
World COPD Day
Chronic Obstructive Pulmonary Disease
Press Conference Kyoto, Japan
November 19, 2006
![Page 2: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/2.jpg)
Opening Remarks Yoshinosuke Fukuchi, MD, PhD
Introduction of GOLD Sonia Buist, MD
New GOLD Guidelines Suzanne Hurd, PhD Klaus F. Rabe, MD, PhD
Additional Comments Peter Calverley, MD
Comments from WONCA Chris van Weel, MD
Closing Remarks Claude Lenfant, MD
World COPD Day Press Conference
![Page 3: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/3.jpg)
Definition of COPDDefinition of COPD
Chronic Obstructive Pulmonary Disease is a preventable and treatable disease with some significant extrapulmonary effects.
The pulmonary component is characterized by airflow limitation that is not fully reversible.
Chronic Obstructive Pulmonary Disease is a preventable and treatable disease with some significant extrapulmonary effects.
The pulmonary component is characterized by airflow limitation that is not fully reversible.
Healthy Alveolus
COPD
![Page 4: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/4.jpg)
Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
The airflow limitation in COPD is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles and gases
Severe COPD leads to respiratory failure, hospitalization and eventually death from suffocation
The airflow limitation in COPD is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles and gases
Severe COPD leads to respiratory failure, hospitalization and eventually death from suffocation
![Page 5: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/5.jpg)
Risk Factors for COPD
NutritionNutrition
InfectionsInfections
Socio-economic Socio-economic statusstatus
Aging PopulationsAging Populations
![Page 6: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/6.jpg)
Dr. A. Sonia Buist Introduction of
GOLD
Dr. A. Sonia Buist Introduction of
GOLDChair, GOLD Executive Committee
Portland, Oregon USA
Chair, GOLD Executive Committee
Portland, Oregon USA
![Page 7: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/7.jpg)
lobal Initiative for Chronic
bstructive
ung
isease
lobal Initiative for Chronic
bstructive
ung
isease
G
OLD
G
OLD
November 19, 2006World COPD Day, Kyoto Japan
![Page 8: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/8.jpg)
Why was GOLD Started?
Why was GOLD Started?
The social and economic burden of COPD is increasing rapidly in countries at all levels of economic development
COPD is under-appreciated, under-diagnosed and under-treated
Important questions about COPD are still unanswered
The social and economic burden of COPD is increasing rapidly in countries at all levels of economic development
COPD is under-appreciated, under-diagnosed and under-treated
Important questions about COPD are still unanswered
![Page 9: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/9.jpg)
COPD is Under-appreciated and Under-diagnosedCOPD is Under-appreciated and Under-diagnosed
Example from Japan:
NICE Survey of COPD prevalence
Carried out in several regions of Japan using standardized methods
Example from Japan:
NICE Survey of COPD prevalence
Carried out in several regions of Japan using standardized methods
![Page 10: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/10.jpg)
COPD Prevalence Rate (adjusted)* in Population 40 years
COPD Prevalence Rate (adjusted)* in Population 40 years
*Adjusted for age, sex, cluster**8.5-10.9% depending on criteria
Study
Fukuchi et al. Respirology 2004;9:458-65
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
0.3%0.3%
8.5%**8.5%**
5.3 vs 0.2M COPD patients in Japan ≥40 years5.3 vs 0.2M COPD patients in Japan ≥40 years
MHW Survey
![Page 11: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/11.jpg)
COPD Prevalence Survey (NICE) in Japan
COPD Prevalence Survey (NICE) in Japan
91%
9%
UndiagnosedDiagnosed
Had prior diagnosis
Did not have prior diagnosis:Fukuchi et al. Respirology 2004;9:458-65
![Page 12: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/12.jpg)
Prevalence of GOLD Stage 1+ COPD1, Guangzhou, ChinaPrevalence of GOLD Stage 1+ COPD1, Guangzhou, China
1 FEV1/FVC<0.70, post BD
MEN15.3%
WOMEN7.6%
![Page 13: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/13.jpg)
Of the six leading causes of death in the United States, only COPD has been increasing steadily since 1970.
Source: Jemal A. et al. JAMA 2005
![Page 14: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/14.jpg)
COPD Mortality by Gender,U.S., 1980-2000
COPD Mortality by Gender,U.S., 1980-2000
0
10
20
30
40
50
60
70
1980 1985 1990 1995 2000
Men
Women
0
10
20
30
40
50
60
70
1980 1985 1990 1995 2000
Men
Women
Num
ber
Death
s x
100
0N
um
ber
Death
s x
100
0
![Page 15: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/15.jpg)
19901990 20202020Ischaemic heart diseaseCerebrovascular diseaseLower resp infectionDiarrhoeal diseasePerinatal disordersCOPDTuberculosisMeaslesRoad Traffic AccidentsLung Cancer
Stomach CancerStomach CancerHIVHIVSuicideSuicide
6th6th
3rd3rd
COPD Mortality WorldwideCOPD Mortality Worldwide
Source: Murray & Lopez. Lancet 1997
![Page 16: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/16.jpg)
Why is COPD Increasing Worldwide?
Why is COPD Increasing Worldwide?
Increase in exposure to risk factors (especially tobacco) in developing countries & in women
Changing demographics globally with more of the population, especially in the developing countries living into the COPD age range
Increase in exposure to risk factors (especially tobacco) in developing countries & in women
Changing demographics globally with more of the population, especially in the developing countries living into the COPD age range
![Page 17: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/17.jpg)
Dr. Suzanne S. Hurd New GOLD Guidelines
Dr. Suzanne S. Hurd New GOLD Guidelines
GOLD Scientific Director
Gaithersburg, Maryland, USA
GOLD Scientific Director
Gaithersburg, Maryland, USA
![Page 18: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/18.jpg)
GOLD ObjectivesGOLD Objectives
Increase awareness of COPD among health professionals, health authorities, and the general public
Improve diagnosis, management and prevention of COPD
Stimulate research in COPD
Increase awareness of COPD among health professionals, health authorities, and the general public
Improve diagnosis, management and prevention of COPD
Stimulate research in COPD
![Page 19: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/19.jpg)
Global Strategy for Diagnosis, Management and Prevention of COPD
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification Burden of COPD Risk factors Pathogenesis, pathology,
pathophysiology Management Practical Considerations
Definition, Classification Burden of COPD Risk factors Pathogenesis, pathology,
pathophysiology Management Practical ConsiderationsRevised 2006
![Page 20: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/20.jpg)
MAJOR CHANGES
Global Strategy for Diagnosis,
Management and Prevention of
COPD
Revised 2006
Revised 2006
![Page 21: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/21.jpg)
Dr. Klaus Rabe New GOLD Guidelines
Dr. Klaus Rabe New GOLD Guidelines
Chair, GOLD Science Committee
Leiden, The Netherlands
Chair, GOLD Science Committee
Leiden, The Netherlands
![Page 22: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/22.jpg)
Global Strategy for Diagnosis, Management and Prevention of COPD
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification Burden of COPD Risk factors Pathogenesis, pathology,
pathophysiology Management Practical Considerations
Definition, Classification Burden of COPD Risk factors Pathogenesis, pathology,
pathophysiology Management Practical ConsiderationsRevised 2006
![Page 23: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/23.jpg)
Definition of COPD
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible.
Its pulmonary component is characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases.
![Page 24: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/24.jpg)
SYMPTOMScoughcough
sputumsputumshortness of breathshortness of breath
EXPOSURE TO RISKFACTORS
tobaccotobaccooccupationoccupation
indoor/outdoor pollutionindoor/outdoor pollution
SPIROMETRYSPIROMETRY
Diagnosis of COPDDiagnosis of COPD
![Page 25: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/25.jpg)
Spirometry for COPD Diagnosis and Classification of Severity
![Page 26: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/26.jpg)
Classification of COPD Severity by Spirometry
Stage I: Mild FEV1/FVC < 0.70 FEV1 > 80% predicted
Stage II: Moderate FEV1/FVC < 0.70 50% < FEV1 < 80% predicted
Stage III: Severe FEV1/FVC < 0.70 30% < FEV1 < 50% predicted
Stage IV: Very Severe FEV1/FVC < 0.70 FEV1 < 30% predicted or
FEV1 < 50% predicted plus chronic respiratory failure
![Page 27: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/27.jpg)
COPD and Co-MorbiditiesCOPD and Co-Morbidities
COPD has significant extrapulmonary (systemic) effects
Weight loss, nutritional abnormalities
Skeletal muscle dysfunction
COPD has significant extrapulmonary (systemic) effects
Weight loss, nutritional abnormalities
Skeletal muscle dysfunction
![Page 28: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/28.jpg)
COPD and Co-MorbiditiesCOPD and Co-Morbidities
COPD patients are at increased risk: • Myocardial infarction, angina
• Osteoporosis
• Respiratory infection
• Depression
• Diabetes
• COPD and lung cancer
COPD patients are at increased risk: • Myocardial infarction, angina
• Osteoporosis
• Respiratory infection
• Depression
• Diabetes
• COPD and lung cancer
![Page 29: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/29.jpg)
Dr. Peter Calverley New GOLD Guidelines
Dr. Peter Calverley New GOLD Guidelines
GOLD Executive/Science Committee
Liverpool, England
GOLD Executive/Science Committee
Liverpool, England
![Page 30: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/30.jpg)
Global Strategy for Diagnosis, Management and Prevention of COPD
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification Burden of COPD Risk factors Pathogenesis, pathology,
pathophysiology Management Practical Considerations
Definition, Classification Burden of COPD Risk factors Pathogenesis, pathology,
pathophysiology Management Practical ConsiderationsRevised 2006
![Page 31: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/31.jpg)
Four Components of Care
Assess and Monitor Disease
Reduce Risk Factors
Manage Stable COPD
Manage Exacerbations
![Page 32: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/32.jpg)
• Relieve symptoms • Prevent disease progression• Improve exercise tolerance• Improve health status• Prevent and treat complications• Prevent and treat exacerbations• Reduce mortality
GOALS of COPD MANAGEMENTVARYING EMPHASIS WITH DIFFERING SEVERITY
![Page 33: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/33.jpg)
DIAGNOSIS AND RISK FACTORS DIAGNOSIS AND RISK FACTORS
Bronchodilator testing no longer mandatory
Post-bd FEV1 still the preferred outcome Symptom assessment, e.g., MRC
dyspnoea Co-morbid pathology to be documented New therapy for smoking cessation More emphasis on indoor pollution
Bronchodilator testing no longer mandatory
Post-bd FEV1 still the preferred outcome Symptom assessment, e.g., MRC
dyspnoea Co-morbid pathology to be documented New therapy for smoking cessation More emphasis on indoor pollution
![Page 34: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/34.jpg)
IV: Very Severe III: Severe II: Moderate I: Mild
Therapy at Each Stage of COPDTherapy at Each Stage of COPD
• FEV1/FVC < 70%
• FEV1 > 80% predicted
• FEV1/FVC < 70%
• 50% < FEV1 < 80%
predicted
• FEV1/FVC < 70%
• 30% < FEV1 < 50% predicted
FEV1/FVC < 70%
• FEV1 < 30% predicted
or FEV1 < 50% predicted plus chronic respiratory failure
Add regular treatment with one or more long-acting bronchodilators (when needed); Add rehabilitation
Add inhaled glucocorticosteroids if repeated exacerbations
Active reduction of risk factor(s); influenza vaccinationAdd short-acting bronchodilator (when needed)
Add long term oxygen if chronic respiratory failure. Consider surgical treatments
![Page 35: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/35.jpg)
OTHER TREATMENT OPTIONSOTHER TREATMENT OPTIONS
Less support for mucolytic and antioxidant therapy
Pneumococcal vaccination Rehabilitation remains a key intervention Oxygen therapy reviewed Surgery and COPD guidance
Less support for mucolytic and antioxidant therapy
Pneumococcal vaccination Rehabilitation remains a key intervention Oxygen therapy reviewed Surgery and COPD guidance
![Page 36: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/36.jpg)
COPD EXACERBATIONSCOPD EXACERBATIONS
COPD exacerbations defined:
“An event in the natural course of the disease characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset, and may warrant a change in regular medication in a patient with underlying COPD.”
Antibiotics with specific advice NIV explained and prioritised Care at home/follow up
COPD exacerbations defined:
“An event in the natural course of the disease characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset, and may warrant a change in regular medication in a patient with underlying COPD.”
Antibiotics with specific advice NIV explained and prioritised Care at home/follow up
![Page 37: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/37.jpg)
Dr. Chris van Weel Comments from
WONCA
Dr. Chris van Weel Comments from
WONCA
GOLD Executive Committee
President, World Organization of Family Physicians
Nijmegen, The Netherlands
GOLD Executive Committee
President, World Organization of Family Physicians
Nijmegen, The Netherlands
![Page 38: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/38.jpg)
Global Strategy for Diagnosis, Management and Prevention of COPD
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification Burden of COPD Risk factors Pathogenesis, pathology,
pathophysiology Management Practical Considerations
Definition, Classification Burden of COPD Risk factors Pathogenesis, pathology,
pathophysiology Management Practical ConsiderationsRevised 2006
![Page 39: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/39.jpg)
COPD Comorbidities
Comorbid heterogeneity Common cause
Heart failure Lung cancer
Complicating Pneumonia
Coincidential Diabetes mellitus Arthritis hip/knee Depression
![Page 40: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/40.jpg)
PATIENT – DISEASE ANOMALY
COPD – The Disease Airflow obstruction Function decline Continuous treatment Lifestyle Regular follow-up ‘Management plan’ Compliance Effects, safety treatment
Patient with COPD Social isolation Unhealthy environment Poverty Poor self-efficacy Multiple health problems Disruptive life conditions Trust & support Safety line
![Page 41: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/41.jpg)
VERTICAL vs HORIZONTAL PROGRAMS OF CAREVERTICAL vs HORIZONTAL PROGRAMS OF CARE
HIV
AIDS
MALARIA
TB
COPD
INTEGRATED PRIMARY CAREINTEGRATED PRIMARY CARE
![Page 42: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/42.jpg)
Practical Considerations: ConclusionsPractical Considerations: Conclusions
Link science to money
Organize special programs through primary care: Ten for 2010
Make a portion (10%) of special program money available for primary care development
![Page 43: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/43.jpg)
Dr. Claude Lenfant Closing Comments
Dr. Claude Lenfant Closing Comments
GOLD Executive Director
Gaithersburg, Maryland, US
GOLD Executive Director
Gaithersburg, Maryland, US
![Page 44: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/44.jpg)
COPD: An Increasing Public Health Problem Worldwide
COPD is increasing in prevalence in many countries of the world
COPD is treatable and preventable
The GOLD program offers a strategy to identify patients and to treat them according to the best medications available
![Page 45: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/45.jpg)
COPD: An Increasing Public Health Problem Worldwide COPD can be prevented by avoidance
of risk factors, the most notable being tobacco smoke
Patients with COPD have multiple other conditions (comorbidities) that must be taken into consideration
GOLD has developed a global network to raise awareness of COPD and disseminate information on diagnosis and treatment
![Page 46: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/46.jpg)
United StatesUnited States
United Kingdom
ArgentinaArgentina
AustraliaAustraliaBrazilBrazil Austria
Canada
CanadaCanada
Chile
Belgium
ChinaChina
DenmarkDenmark
ColumbiaColumbia
Costa Rica
CroatiaCroatia
EgyptEgypt
France
Germany
Greece
IrelandIreland
ItalyItaly
GuatemalaGuatemala
Hong Kong China
Japan
Iceland
IndiaIndia
KoreaKorea
KyrgyzstanKyrgyzstan
LatviaLatvia
LithuaniaLithuania
MexicoMexicoMoldovaMoldova
NepalNepal
Macedonia
Malta
NetherlandsNetherlands
New Zealand
PolandPoland
NorwayNorway
Portugal
Republic of GeorgiaRepublic of Georgia
RomaniaRomania
Russia
SingaporeSlovakia
Slovenia Saudi ArabiaSaudi Arabia
South AfricaSouth Africa
Tatarstan RepublicTatarstan Republic
Spain
SwedenSweden
ThailandThailand
Turkey
SwitzerlandSwitzerland
UkraineUkraine
United Arab EmiratesUnited Arab Emirates
Taiwan ROCTaiwan ROC
VenezuelaVenezuela
Vietnam
Peru
Yugoslavia
Albania
Bangladesh
![Page 47: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/47.jpg)
World Health Organization - Global Alliance Against Chronic Respiratory
Diseases - GARD
![Page 48: World COPD Day Chronic Obstructive Pulmonary Disease Press Conference Kyoto, Japan November 19, 2006](https://reader033.vdocuments.mx/reader033/viewer/2022051515/55150701550346c77d8b4632/html5/thumbnails/48.jpg)
World COPD Day
Chronic Obstructive Pulmonary Disease
Press Conference Kyoto, Japan
November 19, 2006